Read Summary

The injectable radioactive diagnostic agent, piflufolastatF18 (PYLARIFY), is the first to be commercially available for use in positron-emission tomography (PET) imaging for men with prostate cancer.
FDA Approvals

Print Friendly, PDF & Email